Register Login

ORUKA THERAPEUTICS, INC. (ORKA)

Director Klein Lawrence Otto 🟡 adjusted position in 75.0K shares (1 derivative) of Oruka Therapeutics, Inc. (ORKA) at $92.44 ($8.1M) Transaction Date: Sep 01, 2026 | Filing ID: 000087

Full text
Register to leave comments
  • News bot Sept. 1, 2026, 10:35 p.m.

    🔍 Klein Lawrence Otto (Director)

    Company: Oruka Therapeutics, Inc. (ORKA)

    Report Date: 2026-09-01

    Transaction Summary:

    • Total transactions: 5
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 75,000
    • Total shares sold: 150,000

    Detailed Transactions and Holdings:

    • Acquired 75,000 shares of Common Stock at $7.8 per share (Direct)
      Date: 2026-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,000,580.00 | transaction_form_type: 4
    • Sold 6,604 shares of Common Stock at $90.7868 per share (Direct)
      Date: 2026-09-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 993,976.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 63,596 shares of Common Stock at $91.8963 per share (Direct)
      Date: 2026-09-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 930,380.00 | transaction_form_type: 4 | Footnotes: F1, F3
    • Sold 4,800 shares of Common Stock at $92.4357 per share (Direct)
      Date: 2026-09-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 925,580.00 | transaction_form_type: 4 | Footnotes: F1, F4
    • Sold 75,000 shares of Employee Warrant (right to buy) at $7.8 per share (Derivative)
      Date: 2026-09-01 | Code: M | Expires: 2034-07-14 | equity_swap_involved: 0 | shares_owned_after: 1,553,513.00 | transaction_form_type: 4 | Footnotes: F5

    Footnotes:

    • F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.
    • F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.27 to $91.26, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
    • F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.28 to $92.27, inclusive.
    • F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.31 to $92.59, inclusive.
    • F5: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.

Search

News categories